Annals of Intensive Care (Aug 2023)

Diagnostic yield, safety and therapeutic consequences of myocardial biopsy in clinically suspected fulminant myocarditis unweanable from mechanical circulatory support

  • Yann Marquet,
  • Guillaume Hékimian,
  • Guillaume Lebreton,
  • Mathieu Kerneis,
  • Philippe Rouvier,
  • Pierre Bay,
  • Alexis Mathian,
  • Nicolas Bréchot,
  • Juliette Chommeloux,
  • Matthieu Petit,
  • Melchior Gautier,
  • Lucie Lefevre,
  • Ouriel Saura,
  • David Levy,
  • Paul Quentric,
  • Quentin Moyon,
  • Sofia Ortuno,
  • Matthieu Schmidt,
  • Pascal Leprince,
  • Charles-Edouard Luyt,
  • Alain Combes,
  • Marc Pineton de Chambrun

DOI
https://doi.org/10.1186/s13613-023-01169-y
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 12

Abstract

Read online

Abstract Background Fulminant myocarditis is a rare and severe disease whose definite and etiological diagnoses rely on pathological examination. Albeit, myocardial biopsy can be associated with significant morbidity and mortality, its therapeutic consequences are unclear. We conducted a study to determine the diagnostic yield, the safety and the therapeutic consequences of myocardial biopsy in patients with fulminant clinically suspected myocarditis unweanable from mechanical circulatory support (MCS). Methods Monocenter, retrospective, observational cohort study in a 26-bed French tertiary ICU between January 2002 and February 2019. Inclusion of all fulminant clinically suspected myocarditis patients undergoing in-ICU myocardial biopsy while being on MCS. The primary endpoint was the proportion of patients classified as definite myocarditis using Bonaca criteria before and after including myocardial biopsy results. Results Forty-seven patients (median age 41 [30–47], female 53%) were included: 55% died before hospital discharge, 34% could be bridged-to-recovery and 15% bridged-to-transplant. Myocardial biopsy was endomyocardial or surgical in 36% and 64% cases respectively. Tamponade requiring emergency pericardiocentesis occurred in 29% patients after endomyocardial biopsy. After adding the biopsy results in the Bonaca classification algorithm the percentage of definite myocarditis raised from 13 to 55% (p < 0.0001). The rate of biopsy-related treatments modifications was 13%, leading to patients’ recovery in only 4% patients. Conclusions In clinically suspected myocarditis unweanable from MCS, myocardial biopsy increased the rate of definite myocarditis but was associated with a low rate of treatment modification and a significant proportion of adverse events. We believe the benefit/risk ratio of myocardial biopsy should be more carefully weighted in these frail and selected patients than suggested by actual guidelines. Further prospective studies are now needed to determine its value in patients under MCS. Graphical Abstract

Keywords